VEGFA and non-small cell lung carcinoma: So far, only VEGF, the master switch of the angiogenic cascade, has been validated as a therapeutic target for antiangiogenic intervention [7] but no published clinical study has proved that circulating levels of this target are prognostic factors in patients with NSCLC subjected to antiangiogenic therapy [24].